Beta Bionics, Inc.
BBNXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeBeta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring. Valued at $770.5M, BBNX is a small-cap name in its sector. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Market Cap
$770.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.23
EPS (TTM)
$-1.37
EPS (Fwd)
$-2.39
ROE
-22.7%
ROA
-15.0%
Cash
$199.5M
Total Debt
$6.9M
Free CF
-$44.1M
52W Change
27.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $199.5M in cash comfortably exceeding the $6.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$44.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -22.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $179K (2022) to $100.3M (2025), reflecting a 55906% increase over the period.
With cash comfortably exceeding debt, BBNX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Beta Bionics, Inc. and its sector.